CD300a is an immunoreceptor tyrosine-based inhibitory motif (ITIM) containing molecule that belongs to the CD300 family of paired activating/inhibitory receptors. It has been shown that its ligation inhibits activation signals on cells of both myeloid and lymphoid lineages. The ligands for CD300a have not been identified. Here, we show that a CD300a-Ig fusion protein specifically binds to apoptotic cells that are evolutionary apart, such as human and insect cells, suggesting that the ligand has to be conserved.
Introduction
A rising number of publications have described the diversity of paired activating and inhibitory cell surface molecules. [1] [2] The human CD300 family of receptors has 7 members and all of them have an extracellular IgV-like domain. 3 The activating members of this family have a short intracellular tail and associate with immunoreceptor tyrosinebased activation motif (ITAM) containing adaptor proteins, such as DAP12 and FcεRIγ, [3] [4] while the inhibitory members have a long intracellular tail that carry immunoreceptor tyrosine-based inhibitory motifs (ITIM). 3, 5 This multi-gene family is clustered on human chromosome 17 and they are expressed on cells of both lymphoid and myeloid lineages. 3 The gene encoding CD300a has undergone a very significant positive selection, suggesting an essential requirement for the host to evolve and maintaining its function. others. 3, [7] [8] [9] [10] The cytoplasmic tail contains three classical and one non-classical ITIMs.
Thus far, CD300a has been shown to function as an inhibitory receptor. For instance, the ligation of CD300a decreased NK cytotoxic activity, 5, 11 inhibited IgE-mediated degranulation of mast cells 8 , BCR and TCR mediated signaling, 10, 12 reduced FcγRIIa-triggered ROS production in human neutrophils, 7 and suppressed the effects of eotaxin, IL-5, and GM-CSF on human eosinophils. 13 A single nucleotide polymorphism (SNP) that encodes for a non-synonymous mutation in the IgV-like domain of CD300a has been linked to psoriasis susceptibility. 14 Moreover, CD300a has been proposed as a biomarker that can differentiate ulcerative colitis from
Crohn's disease and non-inflammatory diarrhea 15 and for the detection of minimal
For personal use only. on August 31, 2017. by guest www.bloodjournal.org From 4 residual disease in acute lymphoblastic leukemia. 16 We have also published that B cells of HIV infected patients express significantly lower levels of CD300a when compared with healthy donors, suggesting a potential role for this immunomodulatory receptor in the B cell dysfuntion observed during HIV infection. 12 Furthermore, in vivo studies with bispecific antibodies in mice have shown that ligation of CD300a is capable of reversing airway inflammation and tissue remodeling in a model of asthma, 17 abrogating IgE mediated allergic reactions 18 and hampering stem cell factor (SCF) induced anaphylaxis. 19 Altogether, these publications highlight, not only the clinical relevance of the CD300a receptor, but also the potential for targeting this molecule for therapeutic purposes.
Despite the intense interest in CD300a, identification of the ligand has remained elusive.
In the present study, using biochemical, in vitro biological and structural modeling analysis, we demonstrate that the aminophospholipids phosphatidylserine (PS) and especially phosphatidylethanolamine (PE) are the natural ligands for CD300a. The relevance and significance of the interaction between CD300a and PE/PS is demonstrated by the role of this receptor in modulating the engulfment of dead cells, which express these aminophospholipids in the outer leaflet of the plasma membrane.
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Material and methods
Ig fusion proteins
The CD300a-Ig fusion protein and the previously described LAIR-1-Ig 20 were isolated from the culture supernatants of transiently transfected HEK293 cells using protein-ASepharose columns (Amersham Biosciences). The purified proteins were dialyzed in PBS and further processed for conjugation with Alexa Fluor 488 using a monoclonal antibody labeling kit (Molecular Probes, Invitrogen). CD300a-Ig mutants were made using QuikChange Site-Directed Mutagenesis Kit (Stratagene). All constructs were sequenced to confirm their identities.
Flow cytometric analysis and cell binding assays
Flow cytometric experiments were performed in a FACSCalibur or LSRII (BD Biosciences) flow cytometers. Data were analyzed using FlowJo software (Tree Star).
For determination of CD300a expression on macrophages, cells were first blocked with 5% human serum for 15 minutes and then stained with anti-CD300a PE antibody (Beckman Coulter) and anti-CD14 PE-Cy7 (eBiosciences). Isotype controls were used as negative control.
Blood samples from healthy donors were collected under an IRB-approved protocol at were washed twice with wash buffer (PBS containing 1% of FCS) and re-suspended in PBS for flow cytometric analysis. When mentioned, cells were also stained with Annexin V-APC (eBiosciences) and propidium iodide or 7-AAD (Beckman Coulter) to differentiate between dead and live cells. In some experiments the dead population was differentiated using the live/dead cell labeling kit (Molecular Probes, Invitrogen).
Binding assays were also performed on dexamethasone DT40 treated cells and starved Sf-9 insect cells.
To investigate the role of divalent cations in the binding of CD300a-Ig to dead cells, starved PBMCs were pretreated with 5mM EDTA or EGTA for 15 minutes at RT, and then binding assay were performed as described above. In certain experiments, an indirect binding assay was performed; first, cells were incubated for 45 minutes with unlabeled Ig fusion proteins. After the incubation, extensive washes were performed and a secondary detection reagent, anti-human Ig FITC was added, and cells were further incubated for 30 minutes. After that, cells were again washed and re-suspended in PBS for acquisition in the flow cytometer.
In blocking experiments, starved PBMCs were blocked with 5% human serum and then were pre-incubated with unlabeled MFG-E8 and duramycin at four different concentrations of MFG-E8 (2.5-20 Dulbecco's Media (IMDM + Glutamax) supplemented with 10% human AB serum, 2mM Glutamine, 1% Na-Pyruvate, 1% NEAA and 50 ng/ml of recombinant Human M-CSF (R&D Systems). The media was replaced 2-3 times during the differentiation period. 
Statistical analysis
Data were analyzed using GraphPad Prism software Version 5 and plotted as bar graphs or scatter plots. Comparisons were made with the 2-tailed t test with 99% of confidence interval and the two-way ANOVA. P < 0.05 was considered significant. * P < 0.05, **P< 0.01, ***P< 0.001.
Supplemental methods
For details on manufacturing of phospholipid liposomes, surface plasmon resonance (SPR) analysis, structural modeling, sedimentation assay, enzyme linked immuno-sorbent assay (ELISA) and reporter cell assay, see supplemental methods. 
Results
CD300a predominantly binds dead cells
To identify the ligand of CD300a, we generated an Fc fusion protein containing the extracellular domain of CD300a (CD300a-Ig). We tested the binding of CD300a-Ig to starved PBMCs and we observed, as determined by flow cytometric analysis, that CD300a-Ig predominantly binds to cells with low forward scatter (FSC) and low side scatter (SSC), while the negative control fusion protein LAIR-1-Ig did not ( Figure 1A Figure 2B showed that CD300a-Ig specifically binds to immobilized liposomes containing PS, while it does not bind liposomes containing phosphatidylglycerol (PG), phospatidylinositol (PI) purified from liver or liposomes containing PC alone. PE is another phospholipid that is exposed on the outer leaflet of apoptotic cells. [24] [25] This aminophospholipid is synthesized by two independent pathways, and in one of them PS is converted into PE by a PS We have also analyzed the association of CD300a-Ig to PE and PS liposomes using a sedimentation assay ( Figure 2D ). In this assay, the complexes formed by liposomes and proteins are localized in the pellet fraction, while the proteins that are not associated with liposomes remain in the supernatant fraction. Our results showed that CD300a-Ig is in the pellet fraction when it is associated with PE and PS containing liposomes, but absent when liposomes are made only with PC or they are not present ( Figure 2D ). The negative control protein LAIR-1-Ig did not appear in the pellet fraction in any condition (data not shown). Altogether, these results indicate that PS, and especially PE, are the ligands for the immunomodulatory receptor CD300a.
To further prove that there is a specific binding of CD300a to PE and PS, we performed blocking experiments ( Figure 3 ). First, we showed that binding of CD300a-Ig to dead cells is blocked in a dose-dependent manner in the presence of MFG-E8, a PS binding molecule 30 ( Figure 3A) , and in the presence of duramycin, a 19 aminoacid peptide that 1 3 binds PE 31 ( Figure 3B ). Finally, and using the same SPR technology, we showed that Annexin V, another PS binding molecule, 28 blocks the binding of CD300a-Ig to immobilized PS containing liposomes ( Figure 3C ) and that duramycin blocks the binding of CD300a-Ig to immobilized PE containing liposomes ( Figure 3D ). In order to further identify residues that may be involved in the binding of PE and PS, a molecular model of CD300a was generated based on the crystal structure of TIM-4 complexed with PS ( Figure 4C Obtaining the crystal structure of the IgV-like domain of CD300a complexed to PE and PS will clarify this issue. Finally, the mutation of Phe 39 for Ala (F39A) resulted in a decrease in the binding of CD300a-Ig to dead cells. This can be explained by the fact that Phe 39 forms a hydrogen bond with the carboxy group of PS that is absent in PE, and therefore the hydrogen bond is not required. We propose that the observed binding of CD300a-Ig F39A to dead cells is mostly due to the interaction with PE, rather than PS, expressed on the surface of apoptotic cells.
Identification of residues involved in the binding of CD300a to PE and PS
A SNP that encodes for the non-synonymous substitution R94Q in the IgV-like domain of CD300a has been linked to psoriasis susceptibility. 14 We decided to investigate if this clinically important Gln substitution impacts the binding of CD300a to its ligands. Our
results show that CD300a-Ig R94 binds better to dead cells than CD300a-Ig Q94 ( Figure   5A ). SPR analysis show that CD300a-Ig Q94 barely binds to immobilized PS containing liposomes, while the binding to immobilized PE containing liposomes is reduced to one third compared to the binding of CD300a-Ig R94 ( Figure 5B ). The negative control LAIR-1-Ig and the mutant CD300a-Ig D98A do not bind to immobilized PE and PS containing liposomes. Finally, in ELISA experiments, we measured the binding of several CD300a-Ig proteins to purified PE and PS immobilized on a plate ( Figure 5C ).
Results show that CD300a-Ig R94 binds both PE and PS, the latter with lower affinity than the former. However, CD300a-Ig Q94 shows a low affinity to PE and even lower to PS, confirming the results obtained with the SPR analysis. The mutant CD300a-Ig D98A
does not bind neither to PE or PS. Altogether, these results suggest that the susceptibility to psoriasis that is linked to the SNP that encodes for Gln 94 in the IgV-like domain of CD300a is in part due to a change in the ability of the receptor to bind its ligands.
CD300a inhibits the uptake of dead cells
Although many cell types can remove dead cells, professional phagocytes such as macrophages, are the most efficient. This is mainly due to the fact that macrophages express many receptors that are specific for ligands expressed on dead cells. [22] [23] 35 We wanted to know if the CD300a receptor has a role in the phagocytosis of apoptotic cells by macrophages. The human monocyte derived macrophages that we have generated are positive for CD300a cell surface expression ( Figure 6A ). Accordingly, we tested the engulfment of apoptotic cells in the presence of CD300a-Ig, or the protein controls LAIR-1-Ig and Annexin V. The presence of CD300a-Ig resulted in a significant increase
in the number of phagocytosed dead cells by macrophages, while the presence of the protein control LAIR-1-Ig has no effect ( Figure 6B ). When Annexin V was added to the assay we observed a small decrease in the number of engulfed dead cells ( Figure 6B ), although not statistically significant, which is in accordance with published data. 36 To rule out the possibility that the Fc portion of the CD300a-Ig protein has some effect due to its binding to Fc receptors expressed by macrophages, we performed phagocytosis assays after efficiently knocking down CD300a with siRNA technology ( Figure 6C ).
Results presented in Figure 6D showed that macrophages treated with siRNA specific for Finally, and to further study the functional interaction between CD300a and its ligands, we used the BWZ.36 T cell mouse hybridoma reporter cell line transfected with a chimeric receptor consisting of the human CD300a extracellular portion and human CD3ζ transmembrane and intracytoplasmic portions (BWZ.36 CD300a cells). In Figure   6F , we show that CD300a is able to functionally interact with PE, but not with PS. These results suggest that the recognition of PE on the cell surface of dead cells by CD300a delivers a signal that modulates the uptake of apoptotic cells. 
Discussion
In this report we identify PS, and predominantly PE, as the ligands for the human ITIM containing receptor CD300a. The role of PS exposure by the outer leaflet of the plasma membrane and many of its ligands has been extensively studied and several receptors recognizing PS that deliver "eat-me" signals have been identified.
22-23 Here we show for the first time that PE, an aminophospholipid that is also exposed on the outer leaflet of the plasma membrane of dead cells, [24] [25] has an important role in the processes leading to the uptake of apoptotic cells through its recognition by CD300a.
Our results show that CD300a binds late apoptotic/necrotic cells that are characterized by a permeable plasma membrane to a greater extent than early apoptotic cells ( Figure 1B ).
This may be explained by the higher levels of PE and PS exposed on the outer leaflet of the plasma membrane and also by the possibility that the CD300-Ig fusion protein may even be entering to the late necrotic/apoptotic cells. We have studied the interaction of CD300a with PE and PS using liposomes containing different combinations of phospholipids. We show that PC:PS and PC:PE containing liposomes bind to CD300a, and that this binding is specific to PE and PS, because liposomes that do not contain PE or PS do not bind to CD300a. Our attempts to make usable pure PE (and PS) liposomes have not been successful. This was not surprising since it is well known that liposomes containing only PE (or PS) aggregate in the presence of calcium (see Figure 2A for the importance of calcium for binding CD300a-Ig to dead cells). However, when vesicles are prepared using PE or PS in combination with PC, stable bilayers are generated, thereby overcoming the problem of aggregation in the presence of calcium. 37 We have also studied the interaction of CD300a with single pure phospholipids and we show a dose and -4), 27,29,32-33 BAI1, 43 and Stabilin-2. 44 Also, soluble PS-binding molecules have been member of the CD300 family of receptors, recognizes PS exposed on the outer leaflet of the plasma membrane and can modulate phagocytosis. 47 In the present manuscript, we demonstrate that CD300a binds PE and PS and inhibits the uptake of apoptotic cells by macrophages and L929 cells ( Figure 6 ). Our results have strong potential to alter the existing "eat me" signal paradigm in that during the death process, when cells expose PE they may provide a "don't eat me yet" signal. This concept fits nicely with the fact that essentially all immunological responses are the result of tipping the balance between inhibition and activation. The amount of PE exposure likely is a dynamic process that depends on many factors and would be a very interesting area of research to pursue.
Many others have described the expression of PE on the outer leaflet of the plasma membrane of apoptotic cells.
24-25
Our data, along with those from recent publications, 38, [47] [48] showing that CD300 molecules bind lipids and that they are involved in autoimmune processes, are portraying a picture where the CD300 family of proteins is emerging as a sensing network that would be receptive to signals from complex physiological environments, such as those that occur during the engulfment of dead cells. This complexity is further highlighted by differences in the intracellular signaling cascades (ITIMs vs ITAMs), in the heterodimerization potential between different family members and in their diverse pattern of cellular expression.
3-4
Given that CD300a is expressed on cells from both myeloid and lymphoid lineages 3 , and that PS (and probably PE) is not only exposed on apoptotic cells, but also in activated B cells 49 and T cells 47 and in monocytes, 50 future studies addressing the role of this receptor in modulating key immune functions such as cell mediated cytotoxicity and cytokine production, cell differentiation, inflammation and phagocytosis during health and disease are also warranted.
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